Tissue Regenix Group "has the opportunity to become a global commercial organisation"

Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) chief executive Danny Lee and chief financial officer David Cocke speak to Proactive's Thomas Warner after releasing a trading update for 2022. They reveal their highlights from the year before looking ahead to what investors can expect from the business during 2023. Lee says that Tissue Regenix "has the opportunity to become a global commercial organisation."

Contact Details


Proactive UK Ltd

+44 20 7989 0813


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.